Clinical Trial Network

Cystic Fibrosis-Clinical Trial Network Germany – Development of new therapies

Pulmonary function testing

Without clinical trials, development of new drugs would not be possible. The Cystic Fibrosis Clinical Trial Network (CF-CTN Germany) is coordinating clinical trials conducted in the field of cystic fibrosis in Germany with the Mukoviszidose Institut gGmbH as the central contact point for this network. The commitment of cystic fibrosis patients and their willingness to participate in clinical trials is crucial for any successful clinical development leading to new medications.


The CF-CTN

CF-CTN Germany is the short form of Cystic Fibrosis Clinical Trial Network. The biggest and most experienced cystic fibrosis sites cooperate in this network to conduct multicenter clinical trials in the field of cystic fibrosis for the development of new drugs. Usually, pharmaceutical companies initiate such clinical trials. However, the network is also putting patients’ and physicians’ ideas into action by conducting own trial ideas.


Objectives of CF-CTN

  • Enabling patients to get access to innovative therapies in the clinical study setting
  • Working on scientific information to make it generally understandable
  • Involving the patients’ perspective into study set up and conduct
  • Professional coordination to promote Germany as a location for both Investigator Initiated Trials (IITs) and commercial clinical trials for cystic fibrosis
  • Continuous quality improvement of all network members

More than 3,000 patients are reached by the network

Today, the network has a coverage range of more than 3,000 patients. Additional patients can be addressed via certified care centers that are not directly involved in clinical trials. As of January 2018, the trial network has 23 member institutes and 7 partner institutes while it is constantly extended by additional high-quality sites. The member institutes choose delegates to represent them in 3 committees: the executive committee (PD Dr. Jochen Mainz, Dr. Große-Onnebrink, Dr. Stehling), the budget committee and the protocol review committee.


Patient safety first

Without patients participating in clinical trials neither new drugs nor any advances in medicine would be possible. One advantage of participating in clinical trials is early access to innovative therapies. On the other hand, there are risks due to the lack of knowledge regarding the new drugs compared to already approved drugs. Therefore, side effects are possible or the new drug could be not as effective as anticipated. Furthermore, any study participant has to face a lot of additional diagnostics and there is additional time needed. On the other hand, this also reflects a more intensive care which can be beneficial independent of the effectiveness of the medication. It is important to stress that every study participant has the right to withdraw his or her consent to the study participation at any time. Participating in a study is always on a voluntary basis and there must not be any negative impact arising from declining study participation. Patient rights are very strictly regulated by laws and directives. For CF-CTN this is not enough! All studies conducted in the network are reviewed by an independent committee with patient representatives giving active input. Ask your doctor or study team at a CTN-site for more information!


One contact partner – many possibilities

The Mukoviszidose Institut gGmbH is the central point of contact for the network to simplify communication and budget negotiations for network institutes. For studies with complicated inclusion/ exclusion criteria, MI can find solutions using the patient registry.


Your contact person

Dr. Jutta Bend Leitlinien / Neugeborenen-Screening / CF-CTN Germany Coordination Team

Dr. Jutta Bend
Guidelines / newborn screening
Tel.: +49 (0)228 98780-47
Email: JBend(at)muko.info

CF-CTN Germany Coordination Team
Tel.: +49 (0)228 98780-43
Email: CFCTN(at)muko.info


Updated: 16.05.2018